- Home
- CWST vs IONS Comparison
CWST vs IONS Comparison
Compare CWST & IONS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CWST
- IONS
- Stock Information
- Founded
- CWST 1975
- IONS 1989
- Country
- CWST United States
- IONS United States
- Employees
- CWST N/A
- IONS N/A
- Industry
- CWST Environmental Services
- IONS Biotechnology: Pharmaceutical Preparations
- Sector
- CWST Utilities
- IONS Health Care
- Exchange
- CWST Nasdaq
- IONS Nasdaq
- Market Cap
- CWST 5.8B
- IONS 6.8B
- IPO Year
- CWST 1997
- IONS 1991
- Fundamental
- Price
- CWST $89.98
- IONS $72.97
- Analyst Decision
- CWST Strong Buy
- IONS Strong Buy
- Analyst Count
- CWST 8
- IONS 21
- Target Price
- CWST $119.50
- IONS $80.24
- AVG Volume (30 Days)
- CWST 545.0K
- IONS 2.0M
- Earning Date
- CWST 10-30-2025
- IONS 10-29-2025
- Dividend Yield
- CWST N/A
- IONS N/A
- EPS Growth
- CWST 102.54
- IONS N/A
- EPS
- CWST 0.24
- IONS N/A
- Revenue
- CWST $1,795,272,000.00
- IONS $966,957,000.00
- Revenue This Year
- CWST $20.21
- IONS $27.96
- Revenue Next Year
- CWST $7.48
- IONS $2.33
- P/E Ratio
- CWST $377.65
- IONS N/A
- Revenue Growth
- CWST 20.54
- IONS 20.41
- 52 Week Low
- CWST $82.22
- IONS $23.95
- 52 Week High
- CWST $121.24
- IONS $75.49
- Technical
- Relative Strength Index (RSI)
- CWST 51.88
- IONS 62.35
- Support Level
- CWST $82.22
- IONS $71.96
- Resistance Level
- CWST $89.04
- IONS $75.49
- Average True Range (ATR)
- CWST 2.62
- IONS 2.07
- MACD
- CWST 0.39
- IONS -0.42
- Stochastic Oscillator
- CWST 83.62
- IONS 52.18
About CWST Casella Waste Systems Inc.
Casella Waste Systems Inc is a solid waste removal company, providing resource management services to residential, commercial, municipal, and industrial customers. The company's reportable segments on Geographical basis include Eastern, Western and Mid-Atlantic regions through the Resource solution segment. It generates maximum revenue from the Western region segment. The company's services include Recycling, Collection, Organics, Energy, Landfills, Special Waste as well as Professional Services.
About IONS Ionis Pharmaceuticals Inc.
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis received FDA approval in 2024 for Tryngolza for a rare high-triglyceride syndrome, marking its first independent launch.